Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer | MicrobiomeTrials← Back to trialsNCT07812636
Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2026-11-01Est. Completion: 2028-05-01
Enrollment target: 15 participants Locations- Penn State Cancer Institute, Hershey, Pennsylvania, United States
Other microbiome trials you might be interested in
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaUterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, t…
Birmingham, United StatesEst. completion Oct 31, 2027
Phase 2
Recruiting
Atypical Endometrial HyperplasiaFIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system works when given alone or w…
Greeley, United StatesEst. completion Sep 30, 2028